Transvaginal Ultrasound, Non-Obstetrical

Coverage Summary

This policy (Number 0398 addresses non‑obstetrical transvaginal ultrasound (TVUS) for evaluation of suspected pelvic pathology and defines medical necessity and exclusions for TVUS when used for gynecologic disorders and cancer screening. The policy considers TVUS medically necessary for evaluation of suspected pelvic pathology (for example, unexplained postmenopausal bleeding, evaluation of a pelvic mass, acute pelvic pain, assessment of uterus/ovaries/fallopian tubes, and infertility management) and not covered or reimbursable for other indications, including screening for ANY type of cancer.

Policy dates: Effective 2026-03-15; Last review 2026-03-15; Next review 2026-12-15.

Key policy facts

Primary covered indicationEvaluation of suspected pelvic pathology (e.g., postmenopausal bleeding, pelvic mass, acute pelvic pain, infertility management)

Primary disallowed procedure code (note)CPT 76830 (Ultrasound, transvaginal) — not covered or reimbursable when billed for non‑covered indications such as screening

Number of not‑covered ICD‑10 diagnosis codes80+ listed ICD‑10 codes (selected in policy as not covered/reimbursable)

Policy effective date2026-03-15

Ovarian cancer screening outcomeScreening with TVUS (± CA‑125) did not reduce ovarian cancer mortality; no mortality benefit

Medical Necessity Criteria

Medically Necessary

Non-obstetrical transvaginal ultrasound is considered medically necessary when used for evaluation of suspected pelvic pathology.

ALL of the following

Service is transvaginal ultrasound for non-obstetrical indication (CPT 76830).
Used for evaluation of suspected pelvic pathology (e.g., unexplained postmenopausal bleeding, evaluation of pelvic mass, acute pelvic pain, assessment of uterus/ovaries/fallopian tubes, management in infertility such as controlled ovarian hyperstimulation).

Not Covered / Not Reimbursable

Non-obstetrical transvaginal ultrasound is not covered or reimbursable for any other indication including but not limited to screening for ANY type of cancer.

Not covered contexts / diagnoses include

Coding

Not Covered or Reimbursable - ProcedureCPTNot Covered

76830

Ultrasound, transvaginal

Not Covered or Reimbursable - ICD-10 Diagnosis Codes (selected from policy part 1)ICD-10Not Covered

B37.31	Acute candidiasis of vulva and vagina
B37.32	Chronic candidiasis of vulva and vagina
D64.9	Anemia, unspecified
M81.0	Age-related osteoporosis without current pathological fracture
M81.6	Localized osteoporosis [Lequesne]
M81.8	Other osteoporosis without current pathological fracture
M85.9	Disorder of bone density and structure, unspecified
N39.0	Urinary tract infection, site not specified
N60.01	Solitary cyst of right breast
N60.02	Solitary cyst of left breast

1–10 of 145

1/15

Medicare Coverage Determinations notedmixed

No codes listed

Provider Actions

Documentation Required

Support medical necessity with covered diagnosis/procedure codes

Submit TVUS (CPT 76830) only with diagnosis/procedure codes that demonstrate suspected pelvic pathology; services billed without covered codes from the policy's Not Covered ICD‑10 list will be denied.

Affected procedure code: 76830
Avoid ICD-10 codes listed in the policy's Not Covered group (screening/encounter codes)

Denial Risk

Risk of denial for screening indications

Claims for TVUS submitted for screening (including cancer screening) or using the policy-listed screening/encounter ICD‑10 codes (e.g., Z12‑, Z13‑, Z11‑, Z01.419, Z78.0) will be denied as not covered/not reimbursable.

Background & Evidence

Transvaginal ultrasound (TVUS, also TVU or TVS) involves insertion of a transducer into the vagina to obtain high‑resolution pelvic images of the uterus, ovaries, and fallopian tubes and generally provides greater anatomic detail than transabdominal ultrasound.

The U.S. Food and Drug Administration regulates ultrasound systems and transducers as Class II devices via the 510(k) process; these devices are indicated for evaluation of pelvic organs and are intended for use by qualified personnel.

Professional organizations cite TVUS as appropriate for diagnostic evaluation of suspected pelvic pathology — for example, initial assessment of postmenopausal bleeding, characterization and localization of pelvic masses, evaluation of acute pelvic pain, assessment of uterine fibroids, and monitoring during controlled ovarian hyperstimulation — but emphasize that TVUS is not supported as an effective population screening tool for ovarian or endometrial cancer due to poor performance for cancer detection and risk of false positives leading to unnecessary interventions.

Study / Source	Finding
UKCTOCS (Menon et al. 2021)
No significant reduction in ovarian and tubal cancer mortality with annual transvaginal ultrasound screening; stage shift observed but did not translate into lives saved
PLCO Trial (Buys et al. 2011)
Screening with annual CA-125 and TVUS did not reduce ovarian cancer mortality compared with usual care
Systematic reviews (Buhling 2017; Reade 2013)
No demonstrated mortality benefit from annual TVUS screening; high false-positive rates and unnecessary surgeries reported
NCI PDQ ovarian screening summary
Annual CA-125 (6 yrs) and TVUS (4 yrs) did not reduce ovarian cancer mortality; screening associated with false positives and increased oophorectomy
Endometrial biopsy (NCI PDQ / guidelines)
Endometrial biopsy is highly sensitive and specific for endometrial cancer and may be considered in high-risk individuals starting at age 30-35 with 1–2 year intervals; TVUS lacks sensitivity/specificity compared to biopsy
Atkins et al. (PUMBA study, 2025)
Among 1671 with thickened endometrium, 18.4% lacked timely follow-up; one-year endometrial cancer diagnosis rates ~8.8% (thickened) and 7.7% (inadequately visualized)
Jacobs et al. (UKCTOCS nested case-control for endometrium)
TVUS endometrial thickness cutoff (5 mm) showed sensitivity ~77–80% and specificity ~86% for endometrial cancer in postmenopausal women, but role of population screening remains uncertain

Medicare Coverage Determinations

No National Coverage Determination (NCD) or Local Coverage Determination (LCD) was identified in the Medicare coverage determinations noted for this policy.

Medicare entries: No National Coverage Determination found; No Local Coverage Determination found.

Revision History

2025-12-15Annual Review (material)Latest

Annual Review dated 12/15/2025: Revised policy statements regarding screening for cancer and updated formatting standards.

2025-06-15Focused Review (non-material)

Focused review dated 6/15/2025: Removed policy statement for intrauterine device (IUD) insertion, surveillance, or removal.

Screening/Surveillance with Transvaginal Ultrasound (TVUS) and CA-125

Policy-aligned clinical guidance and evidence summaries indicate the following:

ALL of the following

Routine screening for ovarian cancer using TVUS and/or serum CA-125 is not recommended for asymptomatic women at average risk due to lack of mortality benefit and risk of false positives leading to unnecessary invasive procedures.
For individuals with hereditary risk (e.g., BRCA1/2), there is no recommendation for routine TVUS screening for ovarian cancer; CA-125 and pelvic ultrasound may be used for preoperative planning in BRCA-positive individuals undergoing risk-reducing surgery.
For individuals with hereditary syndromes associated with uterine (endometrial) cancer (e.g., Lynch syndrome and listed variants), routine TVUS for endometrial cancer screening lacks sufficient sensitivity and specificity and is not routinely recommended; it may be considered at clinician discretion, particularly in postmenopausal patients.
In premenopausal individuals, TVUS is not recommended for endometrial cancer screening because of variability in endometrial stripe thickness during the menstrual cycle.
For Cowden syndrome / PTEN hamartoma tumor syndrome: TVUS is not recommended for endometrial screening in postmenopausal individuals but may be considered at clinician discretion; not recommended in premenopausal individuals.
Endometrial biopsy is highly sensitive and specific for endometrial cancer and may be considered in high-risk individuals (e.g., Lynch syndrome) starting at age 30-35 and repeated every 1-2 years; TVUS lacks sensitivity/specificity compared to biopsy.
Professional societies and guidelines (NCCN, NCI PDQ, USPSTF, ACR, ACOG) support that available screening tests (TVUS, CA-125) do not reduce ovarian cancer mortality and can lead to harms from false positives.